07:42 AM EDT, 10/21/2025 (MT Newswires) -- Satellos Bioscience ( MSCLF ) said Tuesday the first patient has been dosed in the follow-up study of its therapeutic candidate SAT-3247 in adult males with Duchenne muscular dystrophy (DMD). The trial is underway at St Vincent's Hospital in Melbourne, Australia.

Subject to regulatory and clinical site approvals, Satellos is planning to include up to 10 new participants in Australia. It also plans to open the study in the U.S..

SAT-3247 is designed to repair and regenerate muscle in people living with Duchenne. The study will evaluate longer-term safety, changes in muscle composition by MRI, and functional outcomes in participants with Duchenne who previously completed Part D of the Phase 1b 28-day study.